Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.80.
CTNM has been the subject of several recent research reports. Morgan Stanley reissued an “overweight” rating and set a $25.00 price target on shares of Contineum Therapeutics in a research report on Friday, March 7th. Robert W. Baird dropped their price target on Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of Contineum Therapeutics in a research report on Thursday, January 9th. Finally, Jones Trading began coverage on Contineum Therapeutics in a report on Thursday. They issued a “buy” rating and a $23.00 price target for the company.
View Our Latest Analysis on Contineum Therapeutics
Institutional Inflows and Outflows
Contineum Therapeutics Stock Down 6.6 %
Shares of Contineum Therapeutics stock opened at $6.67 on Thursday. Contineum Therapeutics has a 52-week low of $5.92 and a 52-week high of $22.00. The company has a 50 day moving average of $9.39 and a 200 day moving average of $13.99. The company has a market capitalization of $171.94 million and a P/E ratio of -1.36.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Featured Articles
- Five stocks we like better than Contineum Therapeutics
- How to Start Investing in Real Estate
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.